Q4 2024 Management View CEO Bernard Zovighian highlighted a strong Q4 2024 performance with total company sales growing 9% year-over-year to $1.39 billion and adjusted earnings per share of $0.59. He ...

Edwards Lifesciences Corp (NYSE:EW) reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $0.59 against a ...

Analysts fell to the sidelines weighing in on Edwards Lifesciences (EW – Research Report) and SAGE Therapeutics (SAGE – Research Report) with ...

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...

Stratos Wealth Partners LTD. lowered its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.0% ...

The stock's rise snapped a three-day losing streak.

Edwards Lifesciences Corporation (NYSE:EW) shares are trading higher on Thursday. Stifel analyst Rick Wise upgraded Edwards from Hold to Buy, raising the price forecast to $90 from $75. Wise suggests ...

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...

Pre-earnings options volume in Edwards Lifesciences (EW) is normal with calls leading puts 9:2. Implied volatility suggests the market is ...